Clinical trials: Diffuse Large B Cell Lymphoma Relapsed
- Condition Diffuse Large B Cell Lymphoma Relapsed
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Relapsed or Refractory (R/R) Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL)
A Compassionate Use (CU) Program of Odronextamab
Provide compassionate use of odronextamab
- Conditions
- Relapsed or Refractory (R/R) Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Non-Hodgkin Lymphoma (NHL), High-Grade B-Cell Lymphoma (HGBCL)
- Trial name
- NCT05619367
- Testing
- Odronextamab
- Sponsor
- Regeneron Pharmaceuticals
NHL, Relapsed, Adult, B-cell Lymphoma
Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies
This study is a multi-center study to evaluate the safety of KUR-502 in subjects with refractory/relapsed B-cell NHL or leukemia (ALL or CLL).
- Conditions
- NHL, Relapsed, Adult, B-cell Lymphoma, B-cell Leukemia, DLBCL - Diffuse Large B Cell Lymphoma
- Trial name
- ANCHOR2 (NCT05487651)
- Testing
- KUR-502
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Athenex, Inc.